The real-world safety of ticagrelor among older adults (above 75 years): a pharmacovigilance study from the FDA data

被引：0
|
作者：
Lerman, T. [1 ]
Yacoby, I [1 ]
Fishman, B. [2 ]
Goldman, A. [2 ]
Talmor-Barkan, Y. [1 ]
Itelman, E. [1 ]
Orvin, K. [1 ]
Eisen, A. [1 ]
Kornowski, R. [1 ]
Levi, A. [1 ]
机构：
[1] Rabin Med Ctr, Petah Tiqwa, Israel
[2] Sheba Med Ctr, Ramat Gan, Israel
来源：
EUROPEAN HEART JOURNAL | 2024年 / 45卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页数：1
相关论文
共 50 条
  • [41] Predictors of status epilepticus among older adults-a prospective real-world study
    Assis, Telma
    Cortes, Luan
    Santana, Silas
    Bacellar, Aroldo
    EPILEPSY & BEHAVIOR, 2025, 165
  • [42] Examining the safety of belimumab, especially in children: an analysis of real-world pharmacovigilance data from the US FDA adverse event reporting system (FAERS) database
    Li, Mingming
    Zheng, Ziming
    Li, Jie
    Wang, Cong
    You, Ruxu
    EXPERT OPINION ON DRUG SAFETY, 2024,
  • [43] Post-marketing safety of pimavanserin: a real-world pharmacovigilance study based on the FDA adverse event reporting system (FAERS)
    Liu, Dong
    Zhang, Xueni
    Xu, Haiyan
    EXPERT OPINION ON DRUG SAFETY, 2025,
  • [44] Contrastive analysis on the safety of brand and generic nebivolol: a real-world pharmacovigilance study based on the FDA adverse event reporting system
    Wang, Hongli
    Zhong, Guizun
    Ji, Huanhuan
    Chen, Siqi
    Xie, Qinqin
    Shen, Zhengze
    Jia, Yuntao
    FRONTIERS IN PHARMACOLOGY, 2024, 15
  • [45] A real-world pharmacovigilance study of FDA adverse event reporting system (FAERS) events for niraparib
    Menglin Guo
    Yamin Shu
    Guosong Chen
    Juan Li
    Feie Li
    Scientific Reports, 12
  • [46] A real-world pharmacovigilance study of FDA adverse event reporting system (FAERS) events for sunitinib
    Zhang, Xusheng
    Ren, Xiuli
    Zhu, Tianyu
    Zheng, Wanjin
    Shen, Chengwu
    Lu, Cuicui
    FRONTIERS IN PHARMACOLOGY, 2024, 15
  • [47] A real-world pharmacovigilance study of FDA Adverse Event Reporting System (FAERS) events for venetoclax
    Yang, Yang
    Shu, Yamin
    Chen, Guosong
    Yin, Yanchao
    Li, Feie
    Li, Juan
    PLOS ONE, 2022, 17 (12):
  • [48] A real-world pharmacovigilance study of netarsudil based on the FDA adverse event reporting system (FAERS)
    Xiaomei Xiong
    Xiuwen Zhang
    Fengmin Tang
    Taomin Huang
    BMC Pharmacology and Toxicology, 26 (1)
  • [49] A real-world pharmacovigilance study of raloxifene based on the FDA adverse event reporting system (FAERS)
    Liu, Hao
    Yan, Wei
    Luo, Di
    Li, Jinsong
    Yan, Dezhi
    EXPERT OPINION ON DRUG SAFETY, 2024,
  • [50] A Real-World Pharmacovigilance Study of FDA Adverse Event Reporting System Events for Obeticholic Acid
    Hai, Le
    Wu, Jiaojiao
    Pan, Xiaohong
    Yin, Weicheng
    Wu, Zhishan
    PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2025, 34 (01)
12345